GSHER Digital Learning Academy Cancer Recovery: A to Z for Patients and Families Educational learning resource. Keep your treating clinician involved. Do not change medicines from this workbook. ============================================================ 1.1 Understanding your diagnosis: type, stage, grade and biomarkers START HERE: YOUR REPORT IS INFORMATION, NOT YOUR IDENTITY Hearing the word cancer can make every other sentence difficult to remember. Some people feel frightened, some feel numb, and others immediately begin planning. These reactions do not predict how well treatment will work. You do not have to feel positive all the time to deserve good care. Begin with one manageable task: learn the exact name of your illness and who will explain it to you. Cancer is a large family of diseases. It develops when abnormal cells grow and behave in ways that damage the body. Changes in genes, interactions with surrounding tissue and other biological processes influence this behaviour. It is not evidence that a person thought incorrectly, failed to forgive or lacked willpower. Cancer is generally not passed through ordinary touch, sharing a room or eating together. Some infections increase the risk of particular cancers, but that does not make everyday contact with a person with cancer dangerous. THE NAME MATTERS Ask: where did this cancer begin, and what type of cell is involved? A cancer that started in the breast and spread to bone is usually treated as breast cancer that has spread, rather than as a new primary bone cancer. Blood cancers, brain tumours and childhood cancers may use different classification systems. Two neighbours who both say they have cancer may need completely different medicines and follow-up. A scan may show a suspicious area. A blood test may show an abnormal result. Neither automatically tells the whole story. For many cancers, a tissue sample called a biopsy is examined by a pathologist to confirm the diagnosis and identify its features. Some blood cancers require blood or bone-marrow tests. Your team chooses the appropriate route. Ask which result confirms the diagnosis, which findings remain uncertain and whether further testing could change treatment. READING A PATHOLOGY REPORT Look for your name, identification number, sample date, body site and final diagnosis. Confirm that the sample belongs to you. Reports may include words such as carcinoma, sarcoma, lymphoma, leukaemia or melanoma. These identify different disease families. Terms such as invasive, in situ, differentiation, margins and lymphovascular invasion describe particular findings. Do not interpret a single word without the full report and clinical setting. A margin is an edge of tissue removed during surgery. A positive or involved margin means cancer cells reach an examined edge; a negative or clear margin means they do not. This finding helps the team consider further surgery, radiation or other management. A clear margin does not by itself guarantee that no further treatment is needed. Keep the final report and ask whether it replaces an earlier provisional result. STAGE AND GRADE ANSWER DIFFERENT QUESTIONS Stage describes the extent of disease: its local size or involvement, nearby lymph nodes and whether it has spread to distant sites. Many solid cancers use TNM: T concerns the primary tumour, N the regional lymph nodes and M distant metastasis. Stage groups may use numbers such as I to IV. Not every cancer uses this system, and a stage number should never be compared casually across different cancers. Grade describes how abnormal cells look under the microscope and may help estimate their behaviour. Grade is not the same as stage. A high-grade tumour is not automatically stage IV. A small tumour can have a high grade, and a larger tumour may have different biology. Ask your doctor to explain both using your own report. BIOMARKERS: INFORMATION THAT MAY GUIDE TREATMENT A biomarker is a measurable feature, such as a protein or a gene change, that can help guide diagnosis, treatment or monitoring. For example, certain breast cancers are assessed for hormone receptors and HER2; some other cancers need different molecular tests. This does not mean everyone needs the largest available genetic panel. A useful test has a clear question: what decision could its result change? Testing a tumour for changes acquired by cancer cells is different from testing for an inherited cancer predisposition. A tumour result does not automatically mean children or siblings have inherited the same change. If family history, age or tumour findings suggest inherited risk, ask about genetic counselling. Discuss benefits, limitations, costs, family implications and privacy before testing. An abnormal tumour marker in blood is not proof on its own that cancer is worsening. Some markers rise in noncancerous conditions; some cancers produce no useful marker. A trend, symptoms, scans and clinical examination may be considered together. Do not arrange repeated tests simply because an advertisement promises early certainty. PROGNOSIS WITHOUT FALSE CERTAINTY Prognosis is an estimate of how an illness may behave. Published survival statistics describe groups from earlier periods; they cannot give a precise personal expiry date. Age, general health, cancer biology, treatment access and response can matter. Ask for the most useful explanation for your situation, including what is known, what remains uncertain and when the estimate will be reviewed. CELLUREVA LEARNING NOTE In this course, Reset, Revive, Reprogram and Restore organise practical learning. They do not replace diagnosis, surgery, cancer medicines, radiation or follow-up. The phrase cellular recovery describes support for daily function and wellbeing; it is not a claim that a lifestyle programme can reverse a tumour. Your cancer is not a moral failure. FAMILY EXAMPLE A woman receives a report showing breast cancer and assumes that the word high grade means it has spread throughout her body. Her daughter writes down three questions instead of forwarding the report to social groups: What is the stage? Which receptor tests are pending? What is the treatment goal? At the appointment the team explains that grade and stage are different and completes the missing assessment. The family now has a plan instead of a guess. YOUR DIAGNOSIS CARD Write: exact diagnosis; place of origin; confirmation test and date; stage or risk group; grade if relevant; important biomarkers; pending tests; lead clinician; next appointment. Leave unknown items blank and ask the team. Store paper copies and a secure digital copy. Do not share identifiable reports publicly without considering privacy. TEACH-BACK AND HOME TASK Explain in your own words: the cancer name, the difference between stage and grade, and why a biomarker test may be useful. Ask a family member to listen without correcting every medical term. Finish by writing your three most important questions. If a new severe symptom develops, seek clinical help; do not wait until you understand every report. DEEPER PRACTICE: FOLLOW THE INFORMATION FROM SYMPTOM TO PLAN Imagine that you find a lump. The first question is what it might be. An examination or scan helps locate and describe it. If a biopsy is appropriate, the next question is what cells are present. Once cancer is confirmed, the team may need information about extent and biology. Only then can different treatment options be compared properly. These steps sometimes happen together, and some results take longer than others. A delay in a specialised report does not automatically mean someone has lost your sample. Ask for the expected reporting date and the person who will chase a missing result. A screening test and a diagnostic test serve different purposes. Screening looks for possible disease before a person has symptoms, often in a defined population. An abnormal screening result usually calls for further assessment; it does not automatically confirm cancer. A diagnostic investigation follows a symptom or abnormal finding to establish what is happening. After diagnosis, monitoring tests answer a different question again: how the illness or treatment is changing. Knowing the purpose prevents a person from treating every abnormal test as a complete diagnosis. HOW TO ASK ABOUT A TEST WITHOUT REJECTING IT Useful questions include: What are we trying to find out? How will the answer affect my care? What are the likely risks or discomforts? Do I need to fast or change a medicine? When and how will I receive the result? Is there an equally useful alternative? These questions help you participate. They are not a reason to refuse a necessary investigation based on a frightening internet story. If cost or access is difficult, tell the clinician before quietly missing the appointment; the team may be able to prioritise or arrange support. Before a scan, mention pregnancy possibility, kidney problems, implanted devices, claustrophobia and any previous reaction to contrast. The details needed depend on the scan. Follow the imaging department's instructions rather than those supplied for a different test months earlier. If you take medicines, ask which instructions apply to them. A relative can help organise transport and reports but should not answer every question on your behalf unless you request that support. BIOPSY WORRIES THAT DESERVE A CALM CONVERSATION Many people worry that taking a sample will make cancer spread. The risk and technique depend on the suspected condition and procedure, so ask the specialist directly rather than accepting a blanket claim. In usual practice, biopsy is often essential to choose the right treatment. Avoiding a recommended biopsy can leave the diagnosis uncertain and delay effective care. Tell the team about blood thinners, bleeding problems and allergies before the procedure. Ask what discomfort is expected, what aftercare is needed and which symptoms require a call. The tissue sample may be small. Occasionally it is insufficient, gives an uncertain result or does not fit the clinical picture. A repeat biopsy or expert pathology review may then be advised. This does not by itself mean the first clinician was careless. Sampling, laboratory methods and the complexity of the disease can affect certainty. Ask for the reason in your own case. Keep the written report, and ask how slides or blocks can be made available if another centre needs to review them. UNDERSTANDING COMMON WORD PAIRS Benign and malignant describe different behaviours. A benign growth is not cancer, although it may still cause problems because of size or location. Malignant means cancerous. Localised and metastatic concern extent, rather than the worth or strength of the person. Recurrence means the cancer has returned after a period when it was not detected or was controlled. Progression means the disease has worsened or grown according to the clinical assessment. A new primary cancer is a separate cancer that began independently. Your team distinguishes these possibilities; the course does not ask you to label a new symptom yourself. Complete response or no evidence of disease describes what can currently be detected using the relevant methods. It does not mean every future risk has disappeared. Partial response describes a meaningful reduction according to the method being used. Stable disease can be an important outcome when the goal is control. Do not treat these phrases as school marks. Their meaning depends on the cancer, treatment goal, symptoms and how long the result lasts. Ask the team to explain the next action linked to the result. WHEN TWO REPORTS LOOK DIFFERENT A scan and a pathology report may use different language because they examine different things. A clinical stage may be estimated before an operation; a pathological assessment after surgery can add information from removed tissue. A scan may describe an indeterminate spot that is too small to classify confidently. That is different from confirmed spread. Ask whether an additional scan, biopsy or planned observation is needed. Do not automatically change the word uncertain into the word metastatic. A preliminary report may be revised when additional stains or expert review are completed. Use the most recent final interpretation, while retaining earlier reports for context. If the name or site seems inconsistent, ask for clarification before the next major treatment step. Checking information is a normal part of safe care. You do not have to accuse anyone to say: These two documents appear different; can you explain which information guides the plan? FAMILY HISTORY WITHOUT PANIC Write down which close relatives had cancer, the type if known and the age at diagnosis. A vague statement that many people in the family were ill is less useful than a simple family record. Do not guess a diagnosis from memory if it is uncertain. A genetic counsellor can help decide whether inherited testing is appropriate and explain what a result could mean. Family history may matter even if no test is indicated, and absence of family history does not rule out cancer. An inherited test can produce a clear finding, a negative result or an uncertain finding, depending on the test and situation. An uncertain result should not automatically be treated as proof of high risk or used to recommend major surgery to relatives. Ask for specialist interpretation. Respect each relative's privacy and choices about receiving information. A family discussion should support informed care rather than blame one side of the family for passing on disease. USING NUMBERS KINDLY When you hear a survival percentage, ask which people were studied, what treatment era the number represents and what period it covers. Ask whether the number describes overall survival, cancer-specific survival or another outcome. You do not have to master statistical vocabulary, but the clinician can explain what the number does and does not mean. Some people prefer a broad description; others want detailed estimates. Tell the team what helps you make decisions without overwhelming you. Write down a difficult estimate and revisit it when calmer. Avoid spending every night looking for a better number from a different country or decade. Online calculators may not include your treatment or health details. The most helpful question is often: What can we do now, what should we watch for, and when will we learn more? Uncertainty is uncomfortable, but inventing certainty does not make a plan safer. SECOND CASE: AN INCIDENTAL SCAN FINDING A man being investigated for bowel cancer reads that a small lung spot is indeterminate. He tells his family the cancer is definitely in his lungs and considers abandoning treatment. At review, the specialist explains that the spot is not yet classified and outlines the appropriate next assessment. The family records what is confirmed and what is uncertain in separate columns. This simple distinction prevents an uncertain finding from becoming an unsupported conclusion. WORKSHEET: FOUR COLUMNS FOR EVERY MAJOR RESULT Use one row for each report. Column one: date and test. Column two: what is confirmed. Column three: what remains uncertain. Column four: next action and who is responsible. For example, a biopsy might confirm a particular cancer while biomarker testing is still pending. A scan might answer an extent question while a tiny finding needs follow-up. Show the sheet to the team so misunderstandings are corrected before they are shared widely. Before your next appointment, practise a ninety-second summary. Begin with the exact diagnosis. Add the stage or risk group if confirmed, relevant biomarkers, current symptoms and the question you most need answered. Do not fill gaps with guesses. End with: Please tell me if I have misunderstood anything. This creates a useful starting point for the conversation and allows the clinician to focus on the decision in front of you. END-OF-LESSON REFLECTION The purpose of learning medical terms is to reduce avoidable confusion and make care easier to discuss. You are not expected to become your own pathologist. A reliable diagnosis card, a clear distinction between confirmed and uncertain findings, and a trusted route for questions can be more useful than hours of unstructured searching. Keep ordinary life in view as well: meals, sleep, company and the next practical task remain part of your day. SOURCES AND Sources and further reading https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis https://www.cancer.gov/about-cancer/diagnosis-staging/staging https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment Check your understanding What confirms the cancer type? 1. Pathology and the treating team’s assessment 2. A social-media video 3. One symptom alone Answer: Pathology and the treating team’s assessment Use this action in context: Pathology and the treating team’s assessment. Ask your treating team to adapt the plan to your situation.